Skip to main content
. Author manuscript; available in PMC: 2008 Jun 11.
Published in final edited form as: Anesthesiology. 2008 May;108(5):882–887. doi: 10.1097/ALN.0b013e31816c8a8d

Fig. 3.

Fig. 3

Systemic pretreatment with Tat-PSD-95 PDZ2 significantly reduced halothane MAC. Halothane MAC was measured after intraperitoneal injection of Tat-PSD-95 PDZ2 (n = 8), mutated Tat-PSD-95 PDZ2 (n = 8) and PSD-95 PDZ2 without Tat (n = 6). Note that Tat-PSD-95 PDZ2 dose-dependently reduced halothane MAC. However, mutated Tat-PSD-95 PDZ2 and PSD-95 PDZ2 had no effect. *p < 0.05 vs. vehicle group.